| 영문 | muscular system | 한글 | 근육계통 |
|---|---|---|---|
| 설명 | 근육에 의해 이루어진 하나의 계통을 임의적으로 나누어 부른 말. |
||
| 영문 | male reproductive system | 한글 | 남성생식기계 |
|---|---|---|---|
| 설명 | 남성의 생식기는 여러 기관으로 구성되어 있다. 고환, 부고환, 정관, 정낭, 전립샘, 외부성기(음경) 등으로 구성되는데, 실제적으로 정자를 생성하는 곳은 단 한 곳 고환뿐이며, 나머지 기관은 이를 돕는 기능을 수행하고 있다. 정자는 고환의 정세관이란 곳에서 만들어진 뒤에 밖으로 나와 긴 여정을 시작하게 된다. 그 뒤 부고환을 지나 좀 더 성숙해 진 뒤에 정관에서 정낭의 분비물과 만나고 다시 요도로 나가게 된다. 이때 요도 뒤쪽에 위치하는 전립샘의 분비물이 합쳐지게 되고 이 정액은 외부성기를 거쳐서 밖으로 나가게 된다.  |
||
| 영문 | lymphatic system | 한글 | 림프계 |
|---|---|---|---|
| 설명 | 대개 맥관계라고 하면, 혈관계와 림프관계를 합쳐서 말한다. 이중에 림프에 의해 이루어지는 하나의 계통이다. |
||
| 영문 | immune system | 한글 | 면역체계 |
|---|---|---|---|
| 설명 | 세포성분 및 분자성분의 복합체계로서, 이의 일차기능은 자기(self)를 비자기(not self)로부터 구별하고 외부생물 또는 물질에 대해 방어하는 것이다. 일차적인 세포성분은 림프구와 큰포식세포이며 일차적인 분자성분은 항체와 림포카인이다. |
||
| 영문 | urinary system | 한글 | 비뇨기계통 |
|---|---|---|---|
| 설명 | 비뇨기계통이라하면 콩팥으로부터 시작해서 요관, 방광, 요도에 이르는 일련의 오줌생성 및 저장, 배설기관을 일컫는다. 콩팥은 길이 약 2.5cm, 폭 약 5.1cm, 두께 약 2.5cm, 무게 약 120~160gm으로서, 내측에 콩팥문이 있어 혈관, 신경, 요관이 출입하고 있다. 콩팥은 속질과 겉질로 이루어져 있으며 수질은 10~15개의 추체(오줌을 모으는 역할)를 형성하고 겉질은 약 100만개의 콩팥단위으로 구성되어 있다. 요세관은 토리쪽뇨세관, 헨레고리, 먼쪽뇨세관, 집합관으로 형성되어 있으며, 추체와 술잔, 깔때기를 거쳐 요관으로 연결된다. 콩팥은 혈액을 여과하여 신체 신진대사의 최종산물을 오줌의 형태로 배설하며, 세포외액(extracellular fluid)의 전해질농도를 조절한다. 콩팥에서 형성된 오줌는 요관을 거쳐 방광에서 저장되고 있다가 적당한 시기가 되면 요도를 통해 외계로 배출된다. |
||
| ISIS | image selected in vivo spectroscopy; imaging science and information system; information system-imag... |
|---|---|
| OHA | Oral Hypoglycemic Agents |
| CTA | Canadian Tuberculosis Association; chemotactic activity; chromotropic acid; Committee on Thrombolyti... |
| ICAAC | Interscience Conference on Antimicrobial Agents and Chemotherapy |
| NAHPA | National Association of Hospital Purchasing Agents |
| models, cardiovascular | Theoretical representations that simulate the behaviour or activity of the cardiovascular system, processes, or phenomena; includes the use of mathematical equations, computers and other electronic equipment. (12 Dec 1998) |
|---|---|
| pregnancy complications, cardiovascular | The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow conception and it may or may not have a deleterious effect on the pregnant woman or foetus. (12 Dec 1998) |
| diagnostic techniques, cardiovascular | Methods and procedures for the diagnosis of diseases or dysfunction of the cardiovascular system or its organs or demonstration of their physiological processes. (12 Dec 1998) |
| tuberculosis, cardiovascular | Tuberculosis of the heart, pericardium, or blood vessels. (12 Dec 1998) |
| functional cardiovascular disease | A euphemism for cardiovascular symptoms deemed to be psychogenic. More generally, sometimes used for abnormal cardiac function. (05 Mar 2000) |
| abortifacient agents | Chemical substances that interrupt pregnancy after implantation. (12 Dec 1998) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| abortifacient agents, steroidal | Steroidal compounds with abortifacient activity. (12 Dec 1998) |
| adrenergic agents | Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters. (12 Dec 1998) |
| alkylating agents | Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases. (12 Dec 1998) |
| anti-allergic agents | Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (12 Dec 1998) |
| anti-anxiety agents | Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here. Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants. (12 Dec 1998) |
| anti-arrhythmia agents | Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (12 Dec 1998) |
| anti-asthmatic agents | Drugs that are used to treat asthma. (12 Dec 1998) |
| anticarcinogenic agents | Agents that reduce the frequency or rate of spontaneous or induced tumours independently of the mechanism involved. They differ from antineoplastic agent in that they prevent neoplasms from forming. The anticarcinogenic substances can be divided into three categories. The first consists of compounds that prevent the formation of carcinogens from precursor substances. The second group consists of "blocking agents" which inhibit carcinogenesis by preventing carcinogenic agents from reaching or reacting with critical target sites in the tissues. The third group is the "suppressor agents" which act by suppression of expression of neoplasia in cells previously exposed to carcinogens that would otherwise cause neoplasms. (12 Dec 1998) |